Hiromu Kondo

Nagoya, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 87 publications

Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis.

Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis.

Journal: International journal of clinical oncology

Published: February 27, 2026

The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis.

The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis.

Journal: Oncology

Published: February 24, 2026

Bile-Derived Exosomal miR-196a/-196b as Diagnostic Biomarkers Associated With Tumor Progression in Biliary Tract Cancer.

Bile-Derived Exosomal miR-196a/-196b as Diagnostic Biomarkers Associated With Tumor Progression in Biliary Tract Cancer.

Journal: Cancer science

Published: December 24, 2025

Impact of disintegrants on the structure and disintegration of hydroxypropyl methylcellulose-based amorphous solid dispersion tablets.

Impact of disintegrants on the structure and disintegration of hydroxypropyl methylcellulose-based amorphous solid dispersion tablets.

Journal: Journal of pharmaceutical sciences

Published: August 29, 2025

Impact of disintegrants on the structure and disintegration of hydroxypropyl methylcellulose-based amorphous solid dispersion tablets.

Impact of disintegrants on the structure and disintegration of hydroxypropyl methylcellulose-based amorphous solid dispersion tablets.

Journal: Journal of pharmaceutical sciences

Published: August 29, 2025

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis.

The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 19, 2025

The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis.

The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis.

Journal: Oncology

Published: April 27, 2025

Number of Tumors Stratifies the Therapeutic Response to Atezolizumab plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.

Number of Tumors Stratifies the Therapeutic Response to Atezolizumab plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.

Journal: Oncology

Published: February 10, 2025

Endoscopic liquid biopsy of bile: superior diagnostic and prognostic performance of bile-derived exosomal miR-21-5p for biliary tract cancers.

Endoscopic liquid biopsy of bile: superior diagnostic and prognostic performance of bile-derived exosomal miR-21-5p for biliary tract cancers.

Journal: Journal of gastroenterology

Published: January 28, 2025

Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Neutrophil-to-lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 07, 2025

The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study.

The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study.

Journal: Oncology

Published: December 10, 2024

Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study.

Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study.

Journal: Oncology

Published: July 09, 2024

Showing 1-12 of 87

Last Updated: 09/26/2026